• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Pipeline and Commercial Insight: Moderate to Severe Chronic Nociceptive Pain - Anti-abuse opioids set to prosper Product Image

Pipeline and Commercial Insight: Moderate to Severe Chronic Nociceptive Pain - Anti-abuse opioids set to prosper

  • ID: 1314572
  • August 2010
  • 223 pages
  • Datamonitor

Introduction

The moderate to severe chronic nociceptive pain market has boomed in the years since the removal of generic extended-release oxycodone from the US, growing in value to eclipse $10 billion. However, this reprieve will be short-lived with the pipeline and recently-launched drugs unable to fill the void left by generic erosion of OxyContin (controlled-release oxycodone, Purdue).

Scope

-Analysis of patient segmentation, epidemiology, current treatment approaches, the patient acquisition process and clinical unmet needs

-Breakdown of historic (200509) and future (201019) prescription sales across the seven major markets (US, Japan, France, Germany, Italy, Spain, UK)

-Review of key pipeline trends, issues in clinical trial design and the implications of Risk Evaluation and Mitigation Strategies required by the FDA

-Commercial and clinical assessment of key late-stage pipeline drugs, with key opinion leader comment and region-specific sales forecasts to 2019

Highlights

Aided by continued growth of OxyContin and the launch of opioids incorporating anti-abuse technologies, the market is set to peak at $11.7 billion in 2012. READ MORE >

Overview
Catalyst
Summary
About Datamonitor Healthcare
About the central nervous system pharmaceutical analysis team
Executive Summary
Strategic scoping and focus
Datamonitor insight into the disease market
Related reports
Upcoming related reports

1. Patient Potential
Key findings
Definition of moderate to severe chronic nociceptive pain
Duration
An important distinction is the duration or longevity of pain
Severity
Patients' self-reporting of pain intensity is the most commonly used method
Etiology
Only pain of nociceptive etiology will be included in Datamonitor's chronic pain definition
Symptoms
Severe chronic pain associated with not just pain, but also mental disorders
Diagnosis and treatment rates
Chronic pain is always diagnosed, but treatment does not always ensue
Patient segmentation
Disease severity
Moderate pain is twice as common as severe pain in the chronic population
Disease causation
Back pain and arthritic conditions are the most prevalent chronic pain indications
Pathophysiology
Nociceptive mechanisms predominate in chronic pain
Age
Prevalence of chronic pain increases with age
Epidemiology
Seven major markets
Prevalence of chronic pain in the seven major markets is typically 15-25%
Moderate to severe chronic nociceptive pain represents a substantial population of approximately 67 million patients
Rest of world
India, China and Brazil both possess enormous severe chronic pain market potential
Current management of chronic pain
Analgesics span multiple drug classes
Management of chronic pain by severity
Consequences of inadequately treated chronic pain
Clinical unmet need in moderate to severe chronic nociceptive pain
Side effects of current treatments
Opioid-induced bowel dysfunction presents significant unmet need
Respiratory depression poses a potentially fatal hazard
Opioid addiction and dependence are barriers to painkiller use
Inadequate analgesia
Striking the right balance between analgesia and tolerability can be difficult
Abuse potential of opioids
Incidence is on the rise but Pharma is responding
Other methods of misuse remain difficult to curb
2. Market Overview
Key findings
Market definition for this report
Seven major markets
Current and future market assessment
Seven major markets' value breaks $10 billion barrier but struggles thereafter
Sales volume growth is strong and consistent in all of the seven major markets
Similar growth trends expected in all of the seven major markets
Anti-abuse formulations set to profit at the expense of traditional oral extended-release opioids
Rest of the world snapshot
Current market assessment
The combined worldwide market for chronic moderate to severe pain is worth almost $12 billion
BRIC markets are extremely underserved and contribute just 1% of global sales
The Brazilian, Chinese and Indian markets are showing the strongest growth
OxyContin and Duragesic remain the top two highest selling chronic pain brands in the rest of the world
Patient acquisition process
Trigger point 1: physician education
Guidelines can be of limited use and are not strictly adhered to
Improved pain assessment and utilization of analgesics provides an educational opportunity
Trigger point 2: choice of molecule, method of administration and brand
No direct guidance for the choice of individual opioids and brands means marketing is crucial
Key developers
Purdue Pharma/Mundipharma/Napp Pharmaceuticals
Purdue Pharma is the self-styled 'pain company'
Diversification of research focus and geographic expansion will ensure medium-term stability
Johnson & Johnson
Duragesic propels Johnson & Johnson into second place
King Pharmaceuticals
Strategic acquisitions have forged a significant presence for King in the chronic pain market
Focus on anti-abuse technology creates a niche in the market for King
US-only products leaves opportunity for geographic expansion with commercial partners
Pfizer
Burgeoning pipeline as Pfizer highlights pain as a priority area of research
3. Brand Dynamics
Key findings
Overview of competitive landscape
Current leading treatment options
Comparative forecasts
OxyContin will lose its status as the market leader during the forecast period
Reimbursement: tiering of key brands
OxyContin possesses a more favorable formulary listing relative to its closest rivals
OxyContin (controlled-release oxycodone HCl, Purdue Pharma)
Drug overview
OxyContin is the market-leading opioid painkiller
Drug profile
Product positioning
Gold-standard extended-release opioid in the US market is not without problems
Purdue has countered with a tamper-resistant OxyContin formulation
Controlled-release patent successfully defended by Purdue
SWOT analysis
Brand forecast to 2019
Duragesic (fentanyl transdermal patch, Johnson & Johnson)
Drug overview
Market-leading transdermal patch retains significant share despite generic competition
Drug profile
Product positioning
Distinction from major oral brands has allowed Duragesic to occupy sizeable niche
Recalls have harmed Duragesic's strong brand name
Other patches are beginning to encroach on the transdermal market
Patch formulation is still susceptible to opioid abuse
SWOT analysis
Brand forecast to 2019
Opana ER (extended-release oxymorphone HCl, Endo Pharmaceuticals)
Drug overview
Strong uptake for US-only extended-release oral treatment
Drug profile
Product positioning
Subset of patients may benefit from alternative opioid
Undercutting the price of OxyContin ensured rapid uptake
Crush-resistant formulation in development
Patent litigation leads to early availability of generics
SWOT analysis
Brand forecast to 2019
Ultram ER (extended-release tramadol HCl, Johnson & Johnson)
Drug overview
Opioid with dual mode of action takes novel approach to analgesia
Drug profile
Product positioning
Tramadol formulations useful in less severe patients not responding to weaker non-narcotic analgesics
Influx of competitors expected in the US after Purdue patent deemed unenforceable
SWOT analysis
Brand forecast to 2019
Kadian (extended-release morphine sulfate, Actavis)
Drug overview
Kadian was the best-selling morphine brand for chronic pain in 2009
Drug profile
Product positioning
Once-daily morphine dwarfed by OxyContin
Patent expiry in April 2010 spells the end of market exclusivity
SWOT analysis
Brand forecast to 2019
Avinza (extended-release morphine sulfate, King Pharmaceuticals)
Drug overview
Avinza struggles to keep pace with Kadian
Drug profile
Product positioning
Switching to abuse-resistant formulation will be important for King's success in chronic pain market
SWOT analysis
Brand forecast to 2019
Embeda (extended-release morphine sulfate/naltrexone HCl, King Pharmaceuticals)
Drug overview
Recently launched anti-abuse formulation offers comparable analgesia to Avinza
Drug profile
Product positioning
First-to-market abuse deterrent morphine formulation
Embeda will become King's leading morphine product in moderate to severe chronic pain
Lower price than competitors will encourage switching
SWOT analysis
Brand forecast to 2019
Targin (prolonged-release oxycodone/naloxone, Mundipharma)
Drug overview
First combination analgesic to tackle opioid-induced constipation
Drug profile
Product positioning
Novelty and meeting unmet needs has yielded commercial success for Targin in Germany
Switching from OxyContin is crucial but reimbursement is not guaranteed
SWOT analysis
Brand forecast to 2019
Transtec and Butrans (buprenorphine transdermal patch, Grünenthal/Mundipharma)
Drug overview
Mundipharma/Grünenthal's European-only transdermal patch provides competition for Duragesic
Drug profile
Product positioning
Viable alternative to Duragesic with slight differentiation
SWOT analysis
Brand forecast to 2019
4. Pipeline Overview and R&D Dynamics
Key findings
Pipeline overview
Chronic pain pipeline features long-acting opioids, anti-abuse mechanisms and novel analgesic classes
Classification of pipeline products
Opioids form the basis for the majority of the 23 late-stage clinical developments
Clear shift of research focus away from opioids in order to address unmet needs
Comparative forecasts
Pipeline to contribute almost $2 billion to market value in 2019, with Nucynta ER taking greatest share
Late-stage compounds in development set to make minimal impact
Datamonitor's pipeline assessment summary
Clinical trial design
Patient subpopulations with chronic pain must be targeted individually
A variety of endpoints are used for chronic pain trials
Exalgo clinical trial is a useful benchmark
Exalgo pivotal trial overview
Clinical determination of abuse deterrence is unfeasible
Risk Evaluation and Mitigation Strategies
5. Pipeline Drug Analysis and Forecasts: Opioids
Key findings
Overview of opioids pipeline
Pipeline summary
Comparative forecasts
Definition of current comparator therapy
OxyContin is Datamonitor's gold standard therapy for moderate to severe chronic nociceptive pain
Nucynta ER (extended-release tapentadol HCl, Johnson & Johnson/Grünenthal)
Drug overview
First new opioid molecule to be approved in over 25 years
Comparable efficacy but reduces risk of typical opioid-induced side effects
Johnson & Johnson/Grünenthal are targeting all seven major markets
Drug profile
Clinical trial data
Efficacy data pending, but safety data strengthen claim of improved safety profile
SWOT analysis
Datamonitor drug assessment scorecard for Nucynta ER
Clinical and commercial attractiveness
Superior safety profile over existing treatments is a clear distinction in Nucynta ER's favor
Gradual uptake to be boosted by switching from off-label use of immediate-release formulation
Nucynta ER to benefit from Johnson & Johnson's and Grünenthal's substantial opioid experience
Satisfaction of unmet needs
Evidence suggests Nucynta ER will address the key unmet needs of current treatments
Brand forecast to 2019
Nucynta ER will be well-received in all of the seven major markets
Remoxy (extended-release oxycodone HCl, King Pharmaceuticals)
Drug overview
New tamper-resistant drug aims to reduce abuse potential of long-acting oxycodone
Initially met with response letter - resubmission expected soon
Drug profile
Clinical trial data
Remoxy demonstrates analgesic efficacy and safety typical of other opioids, but direct comparison with existing brands was not carried out
SWOT analysis
Datamonitor drug assessment scorecard for Remoxy
Clinical and commercial attractiveness
Demand for effective opioids with reduced abuse potential addressed by Remoxy
Outlook for Remoxy dealt a blow by new tamper-resistant OxyContin formulation
Satisfaction of unmet needs
Tamper-resistant capsule makes no advances in efficacy or tolerability
Brand forecast to 2019
Remoxy will capture some share from OxyContin but will not emulate its success
ZX002 (controlled-release hydrocodone bitartrate, Zogenix)
Drug overview
First extended-release hydrocodone product reaches Phase III
Drug profile
Clinical trial data
Phase II results show efficacy in moderate to severe chronic osteoarthritis pain with no severe adverse events
SWOT analysis
Datamonitor drug assessment scorecard for ZX002
Clinical and commercial attractiveness
Clinical benefit hard to quantify until Phase III results are available
Clear benefit over competitors should provide a clear entry point into substantial hydrocodone market
Satisfaction of unmet needs
ZX002 does not address key unmet needs identified by Datamonitor and interviewed key opinion leaders
Brand forecast to 2019
Only limited success for first extended-release hydrocodone-only product
TRANSDUR-Sufentanil (sufentanil transdermal patch, Durect Corporation)
Drug overview
Fentanyl analog developed as a transdermal patch formulation
Drug profile
Clinical trial data
Sufentanil patch demonstrates good efficacy with low incidence of application site reactions
SWOT analysis
Datamonitor drug assessment scorecard for TRANSDUR-Sufentanil
Clinical and commercial attractiveness
Durect's sufentanil patch offers distinct improvement over popular Duragesic
Failure to address unmet needs in face of innovative competition may limit reimbursement
Development currently stalled while commercial partner is sought
Satisfaction of unmet needs
New sufentanil patch offers incremental benefits but does not address unmet needs
Brand forecast to 2019
Some transdermal fentanyl patients will try the new sufentanil product, but only modest sales expected
EG-P066 (extended-release morphine sulfate, Egalet)
Drug overview
First erosion-based product provides abuse-resistant extended-release properties
Drug profile
Clinical trial data
Erosion-based morphine compares favorably with established morphine brand in Phase II clinical trial
SWOT analysis
Datamonitor drug assessment scorecard for EG-P066
Clinical and commercial attractiveness
Strong clinical argument for EG-P066's development
Degree of innovation comes under the spotlight when considering commercial factors
Satisfaction of unmet needs
Abuse potential issue is certainly addressed but EG-P066 likely to fail to improve on efficacy and tolerability
Brand forecasts to 2019
Second-to-market abuse-deterrent morphine drug is forecast to eclipse Embeda sales
Other pipeline opioids
CIP-Tramadol ER (extended-release tramadol; Cipher Pharmaceuticals)
Green light for novel tramadol formulation to enter crowded market
Brand forecasts to 2019
Fentos (fentanyl transdermal tape, Hisamitsu/Kyowa Hakko Kirin)
Once-daily fentanyl patch is now available in Japan for cancer pain
Brand forecasts to 2019
Rybix (tramadol HCl orally disintegrating tablet, Victory Pharma)
Victory Pharma launches first orally disintegrating tramadol tablet
Brand forecasts to 2019
ADL5859 and ADL5747 (Adolor/Pfizer)
Potential of delta-opioid agonists for chronic pain remains unclear
BEMA Buprenorphine (buprenorphine buccal disc, BioDelivery Sciences International)
BDSI's buccal buprenorphine disc more suited for acute rather than chronic pain
ELI-154 and ELI-216 (controlled-release oxycodone HCl; controlled-release oxycodone HCl/naltrexone, Elite Pharmaceuticals)
The first once-daily oxycodone formulations are in the pipeline
GRT151 (axomadol, Endo Pharmaceuticals/Grünenthal)
Novel tramadol analog is in Phase II trials
MCP-201 (Mt Cook Pharma)
Proprietary broad-spectrum opioid receptor agonist shows promise
PW4142 (extended-release nalbuphine HCl, Penwest Pharmaceuticals)
Second entry into the market for Penwest likely to be less successful
MGX001 (morphine sulfate/unspecified atypical stimulant, Victory Pharma)
New approach targets the sedatory side effect of morphine
Discontinued/suspended pipeline opioids
6. Pipeline Drug Analysis and Forecasts: Anti-NGF Antibodies
Key findings
Overview of anti-NGF antibodies pipeline
Pipeline summary
Definition of current comparator therapy
Tanezumab (RN624, Pfizer)
Drug overview
Tanezumab is the most advanced anti-NGF antibody in development
Clinical hold enforced on tanezumab after worrisome side effects in osteoarthritis patients
Drug profile
Clinical trial data
Chronic pain clinical trials currently suspended by Pfizer at the FDA's request
Tanezumab clinical program involves 19 separate clinical trials
Phase II data encouraging
Latest Phase III data announced at EULAR 2010
Peripheral neuropathy and paresthesia documented in clinical studies
SWOT analysis
Datamonitor drug assessment scorecard for tanezumab
Clinical and commercial attractiveness
Positive clinical trial results in several types of chronic pain marred by worldwide suspension of trials
First-to-market antibody will benefit from novelty but will be reserved for last-line therapy
Satisfaction of unmet needs
By avoiding an opioid mode of action, tanezumab addresses unmet needs of severe chronic pain therapy
Brand forecasts to 2019
Despite its anticipated restricted label, tanezumab will still launch in the seven major markets
REGN475 (SAR164877, Sanofi-Aventis/Regeneron)
Drug overview
Collaboration between Sanofi-Aventis and Regeneron yields promising anti-NGF antibody
Drug profile
Clinical trial data
Extensive Phase II program for REGN475 underway
Interim analysis of Phase II trial in osteoarthritis recently announced
SWOT analysis
Clinical and commercial attractiveness
Regeneron's antibody benefits from strategic alliance with Sanofi-Aventis
REGN475 may face competition on two fronts
Tanezumab setback may be crippling to the NGF class, or a blessing in disguise
Satisfaction of unmet needs
REGN475 will complement existing therapies well by addressing key unmet needs
Brand forecasts to 2019
Future of anti-NGF antibody class too uncertain to forecast REGN475
Other pipeline anti-NGF antibodies
JNJ-42160443 (Johnson & Johnson)
Clinical development underway in a variety of chronic pain-associated indications
7. Pipeline Drug Analysis and Forecasts: Other Non-Opioid Analgesics
Key findings
Overview of other non-opioid analgesics pipeline
Pipeline summary
Definition of current comparator therapy
Sativex (nabiximols, GW Pharmaceuticals)
Drug overview
Controversial medicinal cannabis product is in worldwide development for difficult-to-treat cancer pain
Drug profile
Clinical trial data
Sativex demonstrates statistically significant efficacy in difficult-to-treat opioid-refractory cancer patients
Phase IIb study conducted in the US
SWOT analysis
Datamonitor drug assessment scorecard for Sativex
Clinical and commercial attractiveness
Efficacy in hard-to-treat refractory cancer pain population
Novelty offset by regulatory risk and restricted labeling
Satisfaction of unmet needs
Cannabis extract goes some way to satisfying the demand for efficacy in patients with severe cancer pain
Brand forecasts to 2019
Despite controversial mode of action, Sativex is still expected to fit into the treatment algorithm across Europe and the US
Other pipeline non-opioid analgesics
Xen2174 (Xenome)
XEN402 (Xenon Pharmaceuticals)
Bibliography
Books and journal papers
Websites
Datamonitor reports
APPENDIX
Forecasting assumptions
New product launches
Generic launches
Methodology
Datamonitor forecast methodology
Product forecasts
Definition of a standard unit
Exchange rates
Methodology for severe cancer pain patient-based forecast
Country group definitions
Rest of European Union
Middle East and North Africa (MENA)
Rest of World
Datamonitor drug assessment scorecard
Contributing experts
About Datamonitor
About Datamonitor Healthcare
About the Disease analysis team
Datamonitor consulting
Disclaimer
List of Tables
Table 1: Classification of pain by pathophysiology
Table 2: Estimated prevalence of key chronic pain indications across the seven major markets, 2010
Table 3: Epidemiology surveys of chronic pain, published between 1998 and 2010
Table 4: Estimates for the prevalence of moderate to severe chronic nociceptive pain in the seven major markets, 2010
Table 5: Estimates for the prevalence of severe chronic pain in the rest of the world, 2010
Table 6: Regional moderate to severe chronic nociceptive pain market sales value ($m) and sales volume (IMS standard units) dynamics across the seven major markets, 2005-2019
Table 7: Purdue and associated companies' chronic pain portfolio, 2010
Table 8: Johnson & Johnson's chronic pain portfolio, 2010
Table 9: King Pharmaceuticals' chronic pain portfolio, 2010
Table 10: Pfizer's moderate to severe chronic nociceptive pain portfolio, 2010
Table 11: Leading treatments for moderate to severe chronic nociceptive pain, 2010
Table 12: Sales forecasts for key brands in moderate to severe chronic nociceptive pain in the seven major markets ($m), 2010-19
Table 13: Representative formulary tier status in the US for leading moderate to severe chronic nociceptive pain brands, 2010
Table 14: OxyContin (controlled-release oxycodone HCl, Purdue) - drug profile, 2010
Table 15: Sales forecasts for OxyContin in the seven major markets ($m), 2010-19
Table 16: Duragesic (fentanyl transdermal patch, Johnson & Johnson) - drug profile, 2010
Table 17: Sales forecasts for Duragesic in the seven major markets ($m), 2010-19
Table 18: Opana ER (extended-release oxymorphone HCl, Endo) - drug profile, 2010
Table 19: Sales forecasts for Opana and Opana ER in the seven major markets ($m), 2010-19
Table 20: Ultram ER (extended-release tramadol HCl, Johnson & Johnson/Grünenthal) - drug profile, 2010
Table 21: Sales forecasts for Ultram ER in the seven major markets ($m), 2010-19
Table 22: Kadian (extended-release morphine sulfate, Actavis) - drug profile, 2010
Table 23: Sales forecasts for Kadian in the seven major markets ($m), 2010-19
Table 24: Avinza (extended-release morphine sulfate, King) - drug profile, 2010
Table 25: Sales forecasts for Avinza in the seven major markets ($m), 2010-19
Table 26: Embeda (extended-release morphine sulfate/naltrexone hydrochloride, King) - drug profile, 2010
Table 27: Sales forecasts for Embeda in the seven major markets ($m), 2010-19
Table 28: Targin (prolonged-release oxycodone/naloxone, Mundipharma) - drug profile, 2010
Table 29: Sales forecasts for Targin in the seven major markets ($m), 2010-19
Table 30: Transtec/Butrans (buprenorphine transdermal patch, Mundipharma/Grünenthal) - drug profile, 2010
Table 31: Sales forecasts for Transtec in the seven major markets ($m), 2010-19
Table 32: Sales forecasts for Butrans in the seven major markets ($m), 2010-19
Table 33: Key pipeline candidates for the treatment of moderate to severe chronic nociceptive pain, 2010
Table 34: Sales forecasts for pipeline products in moderate to severe chronic nociceptive pain in the seven major markets ($m), 2010-19
Table 35: Typical Phase III clinical trial design in chronic pain, 2010
Table 36: Key opioids in late-stage clinical development for the treatment of severe chronic pain, 2010
Table 37: Nucynta ER (extended-release tapentadol HCl) - drug profile, 2010
Table 38: US Phase III open-label 1-year safety trial for tapentadol ER
Table 39: Pivotal European Phase III trial safety results for tapentadol ER
Table 40: Datamonitor's drug assessment scorecard for Nucynta ER in moderate to severe chronic nociceptive pain, 2010
Table 41: Sales forecasts for Nucynta ER in the seven major markets ($m), 2010-19
Table 42: Impacting factors on the revenue of Nucynta ER, 2010-19
Table 43: Remoxy (extended-release oxycodone HCl) - drug profile, 2010
Table 44: Datamonitor's drug assessment scorecard for Remoxy in moderate to severe chronic nociceptive pain, 2010
Table 45: Sales forecasts for Remoxy in the seven major markets ($m), 2010-19
Table 46: Impacting factors on the revenue of Remoxy, 2010-19
Table 47: ZX002 (controlled-release hydrocodone bitartrate, Zogenix) - drug profile, 2010
Table 48: Key facts: Phase III trial of ZX002, 2010
Table 49: Datamonitor's drug assessment scorecard for ZX002 in moderate to severe chronic nociceptive pain, 2010
Table 50: Sales forecasts for ZX002 in the seven major markets ($m), 2010-19
Table 51: Impacting factors on the revenue of ZX002, 2010-19
Table 52: TRANSDUR-Sufentanil (sufentanil transdermal patch, Durect) - drug profile, 2010
Table 53: Datamonitor's drug assessment scorecard for TRANSDUR-Sufentanil in moderate to severe chronic nociceptive pain, 2010
Table 54: Sales forecasts for TRANSDUR-Sufentanil in the seven major markets ($m), 2010-19
Table 55: Impacting factors on the revenue of TRANSDUR-Sufentanil, 2010-19
Table 56: EG-P066 (extended-release morphine sulfate) - drug profile, 2010
Table 57: Datamonitor's drug assessment scorecard for EG-P066 in moderate to severe chronic nociceptive pain, 2010
Table 58: Sales forecasts for EG-P066 in the seven major markets ($m), 2010-19
Table 59: Impacting factors on the revenue of EG-P066, 2010-19
Table 60: Other opioids in late-stage clinical development for the treatment of severe chronic pain, 2010
Table 61: Sales forecasts for CIP-Tramadol ER in the seven major markets ($m), 2010-19
Table 62: Sales forecasts for Fentos in the seven major markets ($m), 2010-19
Table 63: Sales forecasts for Rybix in the seven major markets ($m), 2010-19
Table 64: Discontinued/suspended pipeline GABA modulators
Table 65: Anti-nerve growth factor (NGF) antibodies in late-stage clinical development for the treatment of severe chronic pain, 2010
Table 66: Tanezumab (RN624, Pfizer) - drug profile, 2010
Table 67: Tanezumab - ongoing studies for the treatment of pain, 2010
Table 68: Datamonitor's drug assessment scorecard for tanezumab in moderate to severe chronic nociceptive pain, 2010
Table 69: Sales forecasts for tanezumab in the seven major markets ($m), 2010-19
Table 70: Impacting factors on the revenue of tanezumab, 2010-19
Table 71: REGN475 (SAR164877, Sanofi-Aventis/Regeneron) - drug profile, 2010
Table 72: REGN475 - ongoing studies for the treatment of pain, 2010
Table 73: JNJ-42160443 - ongoing studies for the treatment of pain, 2010
Table 74: Other non-opioid analgesics in late-stage clinical development for the treatment of severe chronic pain, 2010
Table 75: Sativex (nabiximols, GW Pharmaceuticals) - drug profile, 2010
Table 76: Datamonitor's drug assessment scorecard for Sativex in moderate to severe chronic nociceptive pain, 2010
Table 77: Sales forecasts for Sativex in the seven major markets ($m), 2010-19
Table 78: Impacting factors on the revenue of Sativex, 2010-19
Table 79: Datamonitor's launch date estimation for moderate to severe chronic nociceptive pain products in the US, five major EU markets (5EU) and Japan, 2010-19
Table 80: Estimated generic launch dates for the approved moderate to severe chronic nociceptive pain drugs in the seven major markets, 2010-19
Table 81: Datamonitor's drug assessment parameters for key late-stage moderate to severe chronic nociceptive pain pipeline therapies
List of Figures
Figure 58: Methodology for forecasting price to remove impact of currency fluctuations on future trend

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos